Methylphenidate in Adults With Attention Deficit/Hyperactivity Disorder
Launched by HOSPITAL DE CLINICAS DE PORTO ALEGRE · Oct 31, 2016
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well a medication called methylphenidate (MPH) works for adults with Attention Deficit/Hyperactivity Disorder (ADHD). MPH is commonly used to help manage ADHD symptoms, but different people may need different doses, and their responses to the medication can vary. Researchers want to understand what factors—like genetics—might affect how well individuals respond to MPH treatment.
To participate in this study, you need to be of White Brazilian European descent and have been diagnosed with ADHD according to specific guidelines. You should also be eligible to start treatment with immediate-release MPH. However, if you are currently taking stimulant medication, have certain neurological conditions, or have had serious mental health issues like psychosis, you would not be eligible. If you join the trial, you can expect to receive the medication and participate in assessments to help the researchers gather information on how well it works for you and others in the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • White Brazilian of European descent
- • Fulfillment of the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-IV) diagnostic criteria for ADHD
- • Eligibility to immediate-release MPH (IR-MPH) treatment
- Exclusion Criteria:
- • Contraindication for IR-MPH use
- • Current stimulant treatment
- • Evidence of a clinically significant neurological disease that might affect cognition (e.g., delirium, dementia, epilepsy, head trauma, and multiple sclerosis)
- • Current or past history of psychosis
- • Estimated intelligence quotient score lower than 70
About Hospital De Clinicas De Porto Alegre
Hospital de Clínicas de Porto Alegre (HCPA) is a leading academic medical center in Brazil, renowned for its commitment to advancing healthcare through innovative clinical research. As a sponsor of clinical trials, HCPA leverages its extensive expertise in various medical disciplines to conduct rigorous studies aimed at improving patient outcomes and contributing to the global medical community. With a multidisciplinary team of skilled professionals and state-of-the-art facilities, HCPA fosters a collaborative environment that prioritizes ethical standards, patient safety, and scientific integrity in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto Alegre, Rio Grande Do Sul, Brazil
Patients applied
Trial Officials
Eugênio H Grevet, MD, PhD
Principal Investigator
Hospital de Clínicas de Porto Alegre
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials